The honest answer has two parts. Holding onto the muscle you already have while losing fat on a GLP-1 medication is well supported by the evidence. Actively building new muscle during that phase is harder, slower, and depends mostly on one thing: whether you have trained against resistance before. People who are new to it have the most to gain. People who have trained for years are more likely to hold what they have while in a deficit. This article covers what the evidence supports, what it does not, and what the practical version looks like.
Lean mass: everything that is not fat — mostly muscle, but also bone, organ tissue and water. Trials measure lean mass; muscle is the part of it people care about.
What does the evidence actually cover?
It is worth being precise about this, because the strongest evidence is not about GLP-1 medication at all.
The body-composition sub-studies of GLP-1 trials measured what happened to fat and lean mass during treatment. In SURMOUNT-1, approximately 75% of the weight lost was fat mass and 25% was lean mass, in both the tirzepatide arm and the placebo arm (Look 2025). Those sub-studies were not designed to test whether structured resistance training changes that split.
The evidence on protecting muscle during weight loss is much larger, and it comes from the general weight-loss literature. That evidence is what carries over, because the constraint on GLP-1 medication is a calorie deficit — and a calorie deficit behaves like a calorie deficit whatever produced it.
There is no evidence that GLP-1 medication blocks the muscle-building response to training. The obstacles are the deficit itself and the suppressed appetite that makes eating enough protein genuinely difficult.
What does holding muscle take?
Two inputs with strong evidence behind them.
Resistance training. A meta-analysis of 114 trials covering 4,184 people with overweight and obesity found that where resistance training accompanied caloric restriction, lean mass was maintained — an effect size of about −0.3 kg that did not reach statistical significance (Lopez 2022). Trials that included resistance training did not show the lean-mass loss that trials without it do.
In older adults it has been quantified more sharply. Pooling six randomised trials in obese older adults, adding resistance training to caloric restriction prevented an estimated 93.5% of the lean-body-mass loss otherwise seen, without reducing fat loss or total weight loss (Sardeli 2018). That is a small evidence base in one age group, so the exact figure should not be treated as universal — but the direction is not in doubt.
Enough protein. Most guidance during active weight loss sits at 1.2–1.6 g of protein per kg of body weight per day (Leidy 2015). A higher range circulates for people training hard in a deficit — 2.3–3.1 g/kg — and it is worth knowing that this one is measured per kg of fat-free mass, not body weight, and was derived in lean resistance-trained athletes rather than in a general population (Helms 2014). Those are different yardsticks, and confusing them inflates the target substantially. Any target at that end is worth discussing with a doctor or sports dietitian rather than adopting unilaterally.
On a suppressed appetite, protein is the harder of the two. Our protein guide covers how to reach the target on Singapore food when you are not hungry.
Can you actually gain, not just hold?
Sometimes — and training history is the single biggest predictor.
The clearest demonstration is a four-week randomised trial in 40 overweight but untrained young men. Both groups ate at roughly a 40% energy deficit and trained six days a week, combining resistance work with high-intensity intervals. The group eating 2.4 g/kg/day of protein gained 1.2 kg of lean body mass while losing 4.8 kg of fat. The group eating 1.2 g/kg/day gained 0.1 kg of lean mass, which was not different from zero (Longland 2016).
That trial proves gain in a deficit is possible. It also shows what it took: untrained participants, a supervised protocol, six sessions a week, and a very high protein intake over four weeks. Nobody should read it as a typical outcome. The authors note that fat intake differed between the groups as well, so protein cannot take full credit.
The general rule that follows is unglamorous. People who have never trained against resistance have the largest adaptive response available to them, and simultaneous gain and fat loss has been recorded in exactly that group. People who have trained for years are more likely to hold what they have than to add to it while in a deficit — which is still the outcome that matters, because protected muscle is what a maintenance phase is built on. Individual results vary.
There is also a signal that the muscle picture is not uniformly downhill over time. In a 106-person single-arm cohort followed for a year on semaglutide, lean mass fell about 3.0 kg by month seven and then stabilised while fat loss continued, and mean handgrip strength improved by 4.5 kg at twelve months (Alissou 2026). With no comparison group, that study cannot attribute the effect to the medication, and grip strength measures strength rather than muscle mass. It is encouraging rather than conclusive.
What the practical version looks like
Three commitments, in order of how much they matter.
Train against resistance two or three times a week. Full-body sessions covering the major movement patterns. This is the signal that tells the body to keep muscle rather than break it down. Equipment matters far less than consistency and progression.
Hit the protein target most days. Not every day, most days. Put protein on the plate first and eat it while appetite is highest.
Track strength, not the mirror. Loads and repetitions going up over weeks is the earliest and most measurable evidence that the plan is working. Visible change lags well behind it, and body weight tells you almost nothing about this — see why the scale is the worst way to track progress.
At GetLean, our philosophy is that the medication is the catalyst and the training is what decides what you keep — how much training, and how much protein alongside it is set out in full. Individual results vary, and clinical-trial figures describe the populations studied. Before starting resistance training — particularly with any existing joint, cardiac or metabolic condition — ask a doctor whether it is suitable for you.
Common questions
Can you build muscle while on GLP-1 medication?
Holding muscle is well supported. Building it is harder and depends mostly on training history — people new to resistance training have the best chance. A meta-analysis of 114 trials found lean mass was maintained when resistance training accompanied a calorie deficit (Lopez 2022), and a four-week trial in untrained overweight men recorded a 1.2 kg lean-mass gain alongside 4.8 kg of fat loss under supervised conditions (Longland 2016).
Does GLP-1 medication stop you from building muscle?
There is no evidence that it blocks the muscle-building response to training. The constraints are the calorie deficit and the suppressed appetite that makes protein intake harder, rather than the medication acting on muscle tissue.
How much protein do you need to build muscle in a deficit?
Most guidance during weight loss sits at 1.2–1.6 g per kg of body weight per day (Leidy 2015). A higher range of 2.3–3.1 g/kg has been proposed for lean, resistance-trained athletes in a deficit — but that figure is per kg of fat-free mass, not body weight, and comes from a population most people starting treatment are not in (Helms 2014). Worth discussing with a doctor or sports dietitian rather than acting on the raw number.
How long does it take to see muscle changes?
Strength improves within weeks; visible change takes considerably longer. Tracking loads lifted is more useful than tracking appearance, because strength responds first and can be measured every session.
Is it better to build muscle after coming off the medication?
The training does not need to wait. Gaining is slower in a deficit than at maintenance, but resistance training during restriction is what protects lean mass in the first place — in obese older adults it prevented an estimated 93.5% of the lean-mass loss otherwise seen (Sardeli 2018) — and that protected muscle is what a maintenance phase is built on.